3.0.0 9418 2026-07-14T20:22:41Z 2026-07-14T20:22:41Z House H HR 2026-06-24 119 https://www.congress.gov/bill/119th-congress/house-bill/9418 [Congressional Record Volume 172, Number 106 (Wednesday, June 24, 2026)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Ms. BARRAGAN:H.R. 9418.Congress has the power to enact this legislation pursuantto the following:Article 1 Section 8 of the United States Constitution[Page H4246]]]> hsif00 Energy and Commerce Committee House Standing Referred To 2026-06-24T14:04:10Z hswm00 Ways and Means Committee House Standing Referred To 2026-06-24T14:04:05Z 2026-06-24 Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2026-06-24 Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hswm00 Ways and Means Committee 2026-06-24 Introduced in House IntroReferral Intro-H 9 Library of Congress 2026-06-24 Introduced in House IntroReferral 1000 9 Library of Congress B001300 Rep. Barragán, Nanette Diaz [D-CA-44] Nanette Barragán D CA Diaz 44 N J000302 Rep. Joyce, John [R-PA-13] John Joyce R PA 13 2026-06-24 True Health Health 2026-07-09T10:53:45Z 00 2026-06-24 Introduced in House 2026-07-14T20:22:07Z Access to Innovative Treatments Act of 2026

This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so.

Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.

The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.

]]> Access to Innovative Treatments Act of 2026 Display Title 45 Access to Innovative Treatments Act of 2026 2026-06-27T12:53:30Z Short Title(s) as Introduced 101 Access to Innovative Treatments Act of 2026 2026-06-27T12:53:29Z Introduced in House IH Official Title as Introduced 6 To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program. 2026-06-27T12:48:32Z Introduced in House IH Introduced in House 2026-06-24T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-119hr9418ih/xml/BILLS-119hr9418ih.xml 2026-06-24 Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.